Barinthus Biotherapeutics PLC reports a Return on Equity (ROE) of -78.74%.

What is BRNS's dividend yield?

Barinthus Biotherapeutics PLC offers a dividend yield of 0.00%.

What is BRNS's Quality Score?

Our AI rates BRNS's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BRNS?

Our AI Timing Score for BRNS is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BRNS belong to?

Barinthus Biotherapeutics PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Barinthus Biotherapeutics PLC (BRNS) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

BRNS AI Analysis Summary

Our AI summary for BRNS: Barinthus Biotherapeutics PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -78.74%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BRNS

Barinthus Biotherapeutics PLC

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 0.57

0.01 (0.96%) Day Change

Watchlist Portfolio Compare Chart

0.03

D/E

-78.7%

ROE

-56.7%

ROA

0.00%

Div Yield

BARINTHUS BIOTHERAPEUTICS PLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.57 Price 0.01 (0.96%) Day Change	NEWS SCORE: 91

BRNS, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.57
PBV / Sector	0.35 / 44,105.10 GREAT
Earning Per Share	-1.29

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.02 M GREAT
Average 1W Daily Value	0.02 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	-3,180.52 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-56.74 / 185,260.64
ROA Average (%) / Sector	-38.98 / 36,684.64
ROA Change Average (%) / Sector	-439.11 / 422,221.42
ROE (%) / Sector	-78.74 / 243,761.81
ROE Average (%) / Sector	-50.50 / 48,758.38
ROE Change Average (%) / Sector	-446.77 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:44
Symbol	BRNS
Name	BARINTHUS BIOTHERAPEUTICS PLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	40.85 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	23.07 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 20400 Century Boulevard, Germantown, MD, United States, 20874

Phone: 443 917 0966

Website: https://www.barinthusbio.com

Sector: Healthcare >> Biotechnology

Description: Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.